Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 269-212-0 | CAS number: 68201-32-1
Carcinogenicity
Administrative data
Description of key information
No carcinogenicity studies are available on SAS. Most of the long-term studies with suitable structure surrogates (linear alkyl sulfonates, alcohol sulphates, and alpha olefin sulfonates) are inadequate to evaluate the carcinogenic potential in experimental animals, owing to factors such as small numbers of animals, limited numbers of doses, absence of a maximal tolerated dose, and limited histo-pathological examination in the majority of studies. In those studies in which the pathological findings were adequately reported, maximal tolerated doses were not used, and the doses did not produce toxic effects. Subject to these limitations, however, the studies in which animals were administered linear alkyl sulfonates, alcohol sulphates, or alpha olefin sulfonates orally gave no evidence of carcinogenicity; long-term studies in which alpha olefin sulfonates was applied by skin painting studies also showed no effect (IPCS, 1996). In addition, SAS is not classified as mutagenic or clastogenic; or there is no evidence from the repeated dose study that SAS is able to induce hyperplasia and/or pre-neoplastic lesions.
Key value for chemical safety assessment
Justification for classification or non-classification
No classification based on weight of evidence.
Additional information
A low concern of SAS for carcinogenicity exists based on its lack of mutagenicity or clastogenicity; no signs from the repeated dose study that SAS is able to induce hyperplasia and/or pre-neoplastic lesions. Also, there is no indication of a widespread dispersive use, or frequent or long-term human exposure; no evidence of carcinogenicity from limited studies on animals orally or dermally exposed to suitable structural surrogates (linear alkyl sulfonates, alcohol sulphates, or alpha olefin sulfonates). Therefore, we consider that this endpoint has been adequately supported and no additional studies are required.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
